Barclays
PLRX icon

Barclays’s Pliant Therapeutics PLRX Stock Holding History

Barclays’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$336K – 5426
2024
Q3 		$336K Buy
+30,000
New +$375K ﹤0.01% 4017

Other funds holding PLRX

Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Bond & Devick Financial Network
Bond & Devick Financial Network St. Louis Park, Minnesota $414M AUM 11.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Barclays's PLRX Position: Q3 2026 in Review

Barclays reduced its Pliant Therapeutics (PLRX) stake by 100% in Q3 2026, selling an estimated $471 and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #5350.

Barclays first reported a position in PLRX in Q1 2022 and has held it in 19 quarters since. The position peaked at $6.39M in Q4 2023. 18 funds tracked by Wall St. Rank hold PLRX as of Q3 2026.

  • Barclays held 1 share of Pliant Therapeutics worth $1 as of Q3 2026.
  • Barclays sold 425 Pliant Therapeutics shares in Q3 2026, an estimated $471.
  • Pliant Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5350 holding.
  • Barclays first reported a position in Pliant Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Pliant Therapeutics position peaked at $6.39M in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.